Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up
Dermatitis® · 2024
DOI: 10.1089/derm.2023.0220 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Dermatitis®, 2024. Verfasst von Francisco José Navarro-Triviño und 5 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Hand-foot eczema (HFE) are special locations of dermatitis, which are often associated with atopic dermatitis (AD) and have a significant negative impact on the quality of life, demanding a clinically relevant improvement.
Objectives
To evaluate the effectiveness and safety of dupilumab in the treatment of eczema localized in hands and/or feet in patients with moderate-to-severe AD.
Methods
Retrospective multicenter study of adult patients with HFE treated with dupilumab for their AD. Patients with other concomitantly systemic immunosuppressive treatments did not undergo a washout period. The severity of palmar and/or plantar involvement was assessed using the Physician Global Assessment (PGA) scale on a scale of 0 ( = clear) to 5 ( = very severe). Eczema Area and Severity Index (EASI) and NRS-pruritus scales were also evaluated. One hundred percent of patients reached week 16, while 67/84 reached week 52 of follow-up.
Results
A total of 84 patients were included 86.69% of patients showed a reduction in PGA-Hand, and 80.34% in PGA-Foot at week 52, EASI improvement was reached by 83.55% of patients at week 16 and 87.35% at week 52. Reduction of pruritus (≥4 points in NRS-pruritus scale) was 73.01% at week 16 and 80.67% at week 52. No differences in response to dupilumab were observed in the different subtypes of palmo-plantar dermatitis.
Conclusions
The results obtained in our study suggest that dupilumab may be an effective and safe therapeutic option for the treatment of dermatitis localized in hands and/or feet.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
- Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain.
- Department of Dermatology, Hospital Universitario Puerto Real, Cádiz, Spain.
- Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
ORCID-Profile: Francisco José Navarro-Triviño
Zitieren
APA
Navarro-Triviño, F. J., Galán-Gutiérrez, M., Hita, J. C., Ruiz-Villaverde, R., Domínguez-Cruz, J., & Pereyra-Rodríguez, J. J. (2024). Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up. Dermatitis®. https://doi.org/10.1089/derm.2023.0220
Vancouver
Navarro-Triviño FJ, Galán-Gutiérrez M, Hita JC, Ruiz-Villaverde R, Domínguez-Cruz J, Pereyra-Rodríguez JJ. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up. Dermatitis®. 2024. doi:10.1089/derm.2023.0220
BibTeX
@article{NavarroTrivio2024,
author = {Navarro-Triviño, Francisco José and Galán-Gutiérrez, Manuel and Hita, José Carlos-Armario and Ruiz-Villaverde, Ricardo and Domínguez-Cruz, Javier and Pereyra-Rodríguez, José Juan},
title = {Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up},
journal = {Dermatitis®},
year = {2024},
doi = {10.1089/derm.2023.0220}
}
EUVIMED